Skin Analytics
  • NHS
  • AI
  • Research
  • Services
    • Bupa
  • News
  • About Us
  • Careers
  • Contact Us
Select Page

Discussing the systematic review of skin cancer datasets in The Lancet: Skin Analytics response.

by Tim Daly | Nov 16, 2021 | AI, Research, Skin Cancer, Uncategorized

We were delighted to see research into the publicly available skin cancer datasets many use to train AI systems to assess skin cancer published in The Lancet Digital Health last week.  Applying academic rigour to a long known issue around machine learning helps to...

Deploying Safe and Effective AI in Skin Cancer Pathways

by Editor | Jan 27, 2021 | AI, Blog, Regulatory Certification, Research, Skin Cancer

26 January 2021 In December, the British Association of Dermatologist (BAD) President’s Bulletin included an article from Dr Rubeta Matin with an update from the recently formed BAD Artificial Intelligence Working Party Group.  We wanted to welcome the formation of...

Skin Analytics response to NHS AI Code of Conduct

by Editor | Mar 3, 2020 | AI, Anouncement, Blog, Skin Cancer

In July 2019 the Department of Health and Social Care and NHS England published a new code of conduct for the use of digital technology in health and care. As a company at the forefront of using AI algorithms to identify Skin Cancer, we know that AI provides...

Skin Analytics Awarded ISO 13485 Certification

by Editor | Mar 3, 2020 | Anouncement, Blog, Regulatory Certification, Skin Cancer

Skin Analytics is delighted to announce that we are now ISO 13485:2016 certified. ISO 13485:2016 is an internationally recognised quality standard for medical devices and is a pre-requisite for registration as a class II medical device under the MDR. This...

New data shows DERM, our AI skin cancer diagnosis tool, could be as accurate as clinical specialist

by Editor | Oct 17, 2019 | AI, Anouncement, Research, Skin Cancer

New evidence published this week by leading medical journal JAMA shows that our AI technology, DERM, is able to identify melanoma with a similar accuracy as skin cancer specialists. In a study of over 1,500 lesions, DERMcould identify melanoma lesions, with over half...

AI for Skin Cancer… But we are NOT a technology business

by Tim Daly | May 30, 2019 | AI, Blog, Skin Cancer

It is true, we are not a technology company… Perhaps I should explain? When we started our journey to bring better access to high quality skin assessments we focused on how best to use technology do that. As with all blue sky ideas we have had to try quite a few...
« Older Entries

Categories

  • AI
  • Anouncement
  • Blog
  • Funding
  • Regulatory Certification
  • Research
  • Skin Cancer
  • Testimonial
  • Uncategorized

Recent Posts

  • Skin Analytics achieves Class IIa UKCA Mark for DERM. The UK’s first and only Class IIa certified AI dermatology device
  • The Story So Far…
  • Discussing the systematic review of skin cancer datasets in The Lancet: Skin Analytics response.
  • Skin Analytics Receives NHSX Award for AI-Based Skin Cancer Tool
  • Google’s move into skin cancer analysis is great news for patients and Skin Analytics
Skin Analytics Footer Logo

UNITED KINGDOM
Skin Analytics Ltd is a UK registered company.
Number 07919560.
Registered office: Salisbury House, Station Road, Cambridge, CB1 2LA.

Our Service

  • Terms And Conditions
  • Privacy Policy
  • Complaints Policy
Skin Analytics Footer Logo

AUSTRALIA
Skin Analytics Pty Ltd.
ABN 32 619 047 728.
ACN 619 047 728.
Registered Office: 7 Southport St, West Leederville WA 6007

  • Facebook
  • Twitter
Copyright © 2012 - 2021 Skin Analytics - - - - - (USA) Caution -- DERM is an Investigational Device, Limited by United States Law to Investigational Use
×

Our AI technology, DERM is now a Class IIa UKCA certified medical device. This clearance allows Skin Analytics to continue to innovate skin cancer pathways with our partners. This is the next step for Skin Analytics and our technology but it is by no means the end. We will continue to work with regulators as standards of AI in clinical pathways evolve and develop, driving towards clinical excellence.

Find out more